Common Contracts
2 similar License and Collaboration Agreement contracts by Cambridge Antibody Technology Group PLC
EX-4.7 4 dex47.htm AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT1License and Collaboration Agreement • May 5th, 2020 • New York
THIS AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), dated as of September 19, 2003, is made between Genzyme Corporation, a Massachusetts corporation having its principal place of business at One Kendall Square, Cambridge, Massachusetts 02139, U.S.A. (“Genzyme”) and Optein Inc., d/b/a Aptein Inc. (“Aptein”), a Delaware corporation and an Affiliate (as defined herein) of Cambridge Antibody Technology Limited (“CAT”), a company organized under the laws of England and Wales having its principal place of business at The Milstein Building, Granta Park, Cambridge CB1 6GH, England. Genzyme and Aptein are sometimes referred to herein individually as a “Party” and together as the “Parties.”
Standard Contracts
AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT1License and Collaboration Agreement • December 4th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
THIS AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), dated as of September 19, 2003, is made between Genzyme Corporation, a Massachusetts corporation having its principal place of business at One Kendall Square, Cambridge, Massachusetts 02139, U.S.A. (“Genzyme”) and Optein Inc., d/b/a Aptein Inc. (“Aptein”), a Delaware corporation and an Affiliate (as defined herein) of Cambridge Antibody Technology Limited (“CAT”), a company organized under the laws of England and Wales having its principal place of business at The Milstein Building, Granta Park, Cambridge CB1 6GH, England. Genzyme and Aptein are sometimes referred to herein individually as a “Party” and together as the “Parties.”
